Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

Why Pharma Manufacturers Should Partner With Rare Disease Communities

Posted by ZS Editors on Thu, Jul 06, 2017

Patient communities are a valuable asset within the life sciences industry. In the rare disease space, these groups are a vital resource for families battling disease, and serve as much-needed patient representatives to help spur funding, research and scientific advancement. ZS’s Rachael Pius weighs in on why pharmaceutical companies should view these patient communities as partners in clinical development. 

Read More

Topics: Pharma, rare diseases, clinical trials, patient communities, rachael pius, RWE

Designing Effective Incentive Plans for Rare Disease Teams

Posted by Michael Thomas on Mon, Feb 13, 2017

While the pharmaceutical industry is still just skimming the surface when it comes to developing therapies to address the 7,000-plus known rare diseases, drug development is only half of the battle. Organizations that have successfully gained approval for their therapies in the U.S. and abroad face significant challenges when planning their commercial efforts and developing incentive strategies for the field force. To succeed, they often have to get creative.

Read More

Topics: sales compensation, rare diseases, pharmaceuticals, Michael Thomas, incentive plans

Changing the Mindset: Success in Commercializing Rare Disease Drugs

Posted by Michael Thomas on Tue, Apr 26, 2016

There are currently only 314 FDA-approved therapies available among the roughly 7,000 rare diseases that have been identified, according to the Genetic and Rare Diseases Information Center. The global pharmaceutical industry recognizes the unmet need and the opportunity to solve the challenges associated with patients with rare diseases. Current and future pipeline assets offer the pharmaceutical industry an opportunity to bring to market the type of life-changing therapies for patients that add true value where hope is limited.

Read More

Topics: rare diseases, Michael Thomas, organizational alignment, WODC, FDA, pricing and reimbursement

The Power of Social Media

Posted by Alexandra Fulford on Mon, Mar 16, 2015

Social media is an incredibly powerful channel for a myriad of reasons. For pharmaceutical companies, two reasons in particular spring to mind: One is the ability to use social-media listening to gain insights into stakeholder behaviors and needs. Another is the ability of social media to extend the reach of content and improve stakeholder awareness of an issue, for example via a disease awareness campaign.

Read More

Topics: social media, Alexandra Fulford, Pharma, rare diseases

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.